Celldex Therapeutics, Inc. (CLDX) Insider Trading & SEC Filings

Updated Jul 16, 2026 · Last SEC filing 2026-06-29

Celldex Therapeutics, Inc. (CLDX) has filed 18 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-06-29. 3 Form 8-K material event filings were reported by CLDX in the last 90 days. InsiderAlpha tracks every CLDX SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.

About Celldex Therapeutics, Inc. (CLDX)

SEC CIK	0000744218

90-Day SEC Filing Activity

Form 4 filings (90d)	18
Form 8-K filings (90d)	3
Latest Form 4 filing	2026-06-29

Recent CLDX Insider Transactions (Form 4)

Date	Insider	Role	Transaction	Shares	Price	Value	Filing
2025-08-13	Jimenez Freddy A.	SVP GENERAL COUNSEL	S — Open-market sale	341	$23.95	$8K	SEC
2025-08-13	Jimenez Freddy A.	SVP GENERAL COUNSEL	S — Open-market sale	430	$25.41	$11K	SEC
2024-11-18	MARINO JAMES J	Insider	G — Bona-fide gift	10.5K	$0.00	—	SEC
2024-11-11	Marucci Anthony S	PRESIDENT & CEO	P — Open-market purchase	11.5K	$26.82	$308K	SEC

All transactions sourced from SEC EDGAR Form 4 filings for Celldex Therapeutics, Inc. (CLDX). Updated in real time as new filings are submitted to the SEC.

Most-Active CLDX Insiders — Last 90 Days

Insider	Form 4 filings	Total transaction value
Lawver Teri L	1	—
Jimenez Freddy A.	1	—
PENNER HARRY JR	1	—
Torres Denice	1	—
Jain Rita	1	—

Recent CLDX Form 8-K Material Events

2026-07-15 — Item 5.02, 9.01 [SEC]
2026-06-26 — Item 5.02, 5.07, 9.01 [SEC]
2026-05-07 — Item 2.02, 9.01 [SEC]
2026-04-02 — Item 1.01, 8.01, 9.01 · Financing · positive [SEC]
Celldex Therapeutics entered into an underwriting agreement to conduct a secondary public offering of 10,345,000 shares at $29.00 per share, expected to raise approximately $282 million in net proceeds. The offering is expected to close on April 6, 2026, with underwriters holding
2026-02-25 — Item 2.02, 9.01 · Earnings · neutral [SEC]
Celldex Therapeutics issued a press release on February 25, 2026 announcing its financial results for Q4 2025 and full year 2025. This is a routine quarterly/annual earnings disclosure with no indication of material operational changes, clinical milestones, regulatory events, or

Recent Insider Filings

2026-06-29 — Lawver Teri L (SVP & Chief Commercial Officer)
2026-06-29 — Jimenez Freddy A. (SVP & GENERAL COUNSEL)
2026-06-29 — Young Diane C. (SVP, CHIEF MEDICAL OFFICER)
2026-06-29 — Heath-Chiozzi Margo (SVP OF REGULATORY AFFAIRS)
2026-06-29 — Martin Samuel Bates (SVP AND CFO)

Form 4 Transaction Code Reference

SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in CLDX insider filings:

P	Open-market purchase by the insider
S	Open-market sale by the insider
A	Grant, award, or other acquisition from the issuer
M	Exercise or conversion of derivative security (e.g. options)
F	Payment of exercise price or tax liability via share withholding
G	Bona-fide gift of securities
D	Disposition to the issuer (e.g. share buyback participation)
J	Other acquisition or disposition
X	Exercise of in-the-money or at-the-money derivative security
C	Conversion of derivative security
V	Transaction voluntarily reported earlier than required

CLDX Insider Trading — FAQ

What is the latest insider trade for CLDX?: Celldex Therapeutics, Inc. (CLDX) had 18 insider filings in the last 90 days, with the most recent on 2026-06-29. InsiderAlpha tracks every Form 4, 10-K, 10-Q, and 8-K filing in real time.
How many insiders are buying CLDX stock?: 0 insider purchases of CLDX were filed in the last 90 days.
How many insiders are selling CLDX stock?: 0 insider sales of CLDX were filed in the last 90 days.
Where can I see CLDX SEC filings (Form 4, 10-K, 10-Q, 8-K)?: InsiderAlpha aggregates every CLDX SEC filing — Form 4 insider transactions, 10-K and 10-Q quarterly reports, and 8-K material event disclosures — in one timeline.

Learn More

Open the live CLDX dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.